About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PFE - Pfizer| Previous Close | $38.48 | Open | $38.61 |
| Volume | 29.45M | Market Cap | 213.75B |
| Yield | 3.90 % | Last Dividend | $1.50 |
| A top Wall Street analyst gamed out 12 s... | 2:54 PM |
| Moderna's coronavirus vaccine candidate could report positive efficacy results as soon as late October, a top Wall Street analyst said. Jefferies biot... | |
| Pfizer Deal Pushes Carlyle-Backed Drug D... | 10:45 AM |
| https://www.investing.com/news/pfizer-deal-pushes-carlylebacked-drug-developer-ppd-to-record-2251228 | |
| PPD Signs New Service Agreement with Pfi... | 8:00 AM |
| WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pf... | |
| The rich will be the first to get vaccin... | 08/02/20 |
| By James PatonWealthy countries have already locked up more than a billion doses of coronavirus vaccines, raising worries that the rest of the world w... | |
| New Russian COVID-19 Vaccine is Schedule... | 08/01/20 |
| Russia, which has reported more than 822,000 cases of COVID-19 and is currently the world???s fourth most COVID-infested country, has concluded plans ... | |
| Red Flags Soar As Big Pharma Will Be Exe... | 08/01/20 |
| Red Flags Soar As Big Pharma Will Be Exempt from COVID-19 Vaccine Liability Claims Tyler Durden Sat, 08/01/2020 - 12:35 Last week we warned readers to... | |
| The US government just spent $2.1 billio... | 07/31/20 |
| The US government invested $2.1 billion in the development and delivery of 100 million doses of the vaccine candidate from Sanofi and GlaxoSmithKline ... | |
| We just got one step closer to finding o... | 07/31/20 |
| Hello, Somehow, we've made it to the end of July. If you can believe it, that means we here in the US have been in this pandemic for five months. Is a... | |
| This might be the best coronavirus vacci... | 07/31/20 |
| Several coronavirus vaccine trials have reached the final Phase 3 stage of testing ahead of potential approvals from regulators. Researchers are targe... | |
| PFE Stock Down 0.5%, Pfizer, BioNTech to... | 07/31/20 |
| PFE stock is likely to breakout and rally as Pfizer together with BioNTech will supply Japan with 120 million doses of their vaccine. | |
| 'Partial' Lockdowns Expand In Europe, Ne... | 07/31/20 |
| 'Partial' Lockdowns Expand In Europe, New COVID-19 Cases Climb In China, Hong Kong: Live Updates Tyler Durden Fri, 07/31/2020 - 08:49 US markets are b... | |
| COVID-19: Two Late Stage Vaccine Trials ... | 07/31/20 |
| DUBLIN--(BUSINESS WIRE)--ResearchAndMarkets.com published a new article on the vaccines industry "COVID-19: Two Late Stage Vaccine Trials Underway in ... | |
| Pfizer, BioNTech to supply 120 mn doses ... | 07/31/20 |
| BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy | |
| Japan secures 120 million doses of poten... | 07/31/20 |
| Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the ... | |
| Pfizer, BioNTech to supply 120 million d... | 07/31/20 |
| The United States has signed a similar deal with Pfizer and BioNtech for 100 million doses for nearly $2 billion, which amounts to a $39 price tag for... | |
| The coronavirus vaccine from Sanofi and ... | 07/31/20 |
| Drug makers Sanofi and GlaxoSmithKline are set to receive up to $2.1 billion in funding for their potential coronavirus vaccine. The funding comes fro... | |
| Japan to get 120 mn doses of Covid-19 va... | 07/31/20 |
| BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy. | |
| Menopausal Hot Flashes Industry Assessme... | 07/31/20 |
| DUBLIN--(BUSINESS WIRE)--The "Menopausal Hot Flashes - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. ... | |
| Pfizer, BioNTech to Supply 120 Million D... | 07/31/20 |
| The companies said, assuming success of the vaccine in clinical studies, they are on track to seek regulatory review for the vaccine as early as Octob... | |
| Pfizer, BioNTech to supply 120 million d... | 07/31/20 |
| Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in t... | |
| Pfizer, BioNTech to supply 120 mln doses... | 07/31/20 |
| Read more about Pfizer, BioNTech to supply 120 mln doses of coronavirus vaccine to Japan on Devdiscourse | |
| Pfizer and BioNTech to Supply Japan with... | 07/31/20 |
| Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to | |
| Bill Gates: We will have a coronavirus v... | 07/30/20 |
| Billionaire philanthropist Bill Gates has been warning about the threat of a pandemic for years. Gates told Insider US coronavirus testing here is "wo... | |
| ARYA SCIE : Cerevel Therapeutics and Ary... | 07/30/20 |
| Leading institutional investors commit $320 million through a common stock private investment in public equity led by Bain Capital, Perceptive Advisor... | |
| COVID-19 Impacts: Allergy Rhinitis Drugs... | 07/29/20 |
| Technavio has been monitoring the allergy rhinitis drugs market and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of almo... | |
| Ropes & Gray launches new strategic cons... | 07/29/20 |
| Boston-based Ropes & Gray on Wednesday became the latest Big Law firm to beef up its consulting offerings, announcing a combined data analytics, behav... | |
| Front Lines Against Coronavirus: Gilead,... | 07/29/20 |
| Ahead of earnings from two of the most closely watched biotechs??? Moderna Inc (NASDAQ: MRNA ) and Gilead Sciences, Inc. (NASDAQ: GILD )???one thing s... | |
| Russia Hopes To Register World's First C... | 07/29/20 |
| Russia Hopes To Register World's First COVID-19 Vaccine By Aug. 12 Tyler Durden Wed, 07/29/2020 - 14:45 As the English-language science and financial ... | |
| Pfizer Analysts See 'Surprisingly Strong... | 07/29/20 |
| Pfizer Inc. (NYSE: PFE ) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter ??? an... | |
| Hold rating | 07/30/20 |
| Morgan Stanley maintains Equal-Weight rating and raises Price Target from $36.00 to $42.00 | |
| Buy rating | 07/29/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $39.00 to $42.00 | |
| Hold rating | 07/29/20 |
| UBS maintains Neutral rating and raises Price Target from $37.00 to $39.00 | |
| Buy rating | 06/16/20 |
| SVB Leerink initiates coverage with Market Perform rating and announces Price Target of $40.00 | |
| Hold rating | 06/01/20 |
| JP Morgan maintains Neutral rating and lowers Price Target from $37.00 to $36.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Free Biotech Holdings | Scientia Equity Research | 100.00 % | Follow |
| M.I.B | Jay | 93.00 % | Follow |
| Swingtrades | R. belegger | 83.00 % | Follow |
| Tech Trades | Tech Trades | 83.00 % | Follow |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
